{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:15Z","timestamp":1788401595365,"version":"build-2803163510"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Determining whether vaccine efficacy wanes is important for individual and public decision making. Yet, quantification of waning is a subtle task. The classical approaches cannot be interpreted as measures of declining efficacy unless we impose unreasonable assumptions. Recently, formal causal estimands designed to quantify vaccine waning have been proposed. These estimands can be bounded under weaker assumptions, but the bounds are often too wide to make claims about the presence of waning. We propose a different approach: a formal test to assess whether a treatment effect is constant over time at the individual level. This test provides a considerable power gain over existing approaches and is valid under interpretable assumptions in vaccine trials. We illustrate the increase in power through real and simulated examples, using 3 different approaches to compute the test statistics. Two of these approaches are based solely on summary data, accessible from existing clinical trials. Beyond our test, we also give new results that bound the waning effect. We use our methods to reanalyze data from a randomized controlled trial of the BNT162b2 COVID-19 vaccine. While a prior analysis did not establish waning, our test rejects the null hypothesis of no waning.<\/jats:p>","DOI":"10.1093\/aje\/kwag118","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:48:58Z","timestamp":1782859738000},"page":"2469-2475","source":"Crossref","is-referenced-by-count":0,"title":["A simple and powerful test of vaccine waning"],"prefix":"10.1093","volume":"195","author":[{"given":"Gell\u00e9rt","family":"Per\u00e9nyi","sequence":"first","affiliation":[{"name":"Institute of Mathematics , \u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne (EPFL), Rte Cantonale, 1015, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Janvin","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology , Department of Biostatistics, University of Oslo, 0372 Oslo, Norway"},{"name":"Department of Surgery and Anesthesiology , Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats J","family":"Stensrud","sequence":"additional","affiliation":[{"name":"Institute of Mathematics , \u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne (EPFL), Rte Cantonale, 1015, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026090221220231500_ref1","article-title":"Debiasing hazard-based, time-varying vaccine effects using vaccine-irrelevant infections: an observational extension of a pivotal phase 3 COVID-19 vaccine efficacy trial","author":"Ashby","year":"2025"},{"issue":"6","key":"2026090221220231500_ref2","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/infdis\/jiu497","article-title":"Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults","volume":"211","author":"Bernstein","year":"2015","journal-title":"J Infect Dis"},{"issue":"6","key":"2026090221220231500_ref3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-025-01250-9","article-title":"How hazard ratios can mislead and why it matters in practice","volume":"40","author":"Dumas","year":"2025","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"2026090221220231500_ref4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/aje\/kws260","article-title":"Correlated infections: quantifying individual heterogeneity in the spread of infectious diseases","volume":"177","author":"Farrington","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"27","key":"2026090221220231500_ref5","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1002\/sim.9001","article-title":"Assessing vaccine durability in randomized trials following placebo crossover","volume":"40","author":"Fintzi","year":"2021","journal-title":"Stat Med"},{"issue":"8","key":"2026090221220231500_ref6","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.7326\/M20-8149","article-title":"A deferred-vaccination design to assess durability of COVID-19 vaccine effect after the placebo group is vaccinated","volume":"174","author":"Follmann","year":"2021","journal-title":"Ann Intern Med"},{"issue":"1","key":"2026090221220231500_ref7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.0006-341X.2002.00021.x","article-title":"Principal stratification in causal inference","volume":"58","author":"Frangakis","year":"2002","journal-title":"Biometrics"},{"issue":"4","key":"2026090221220231500_ref8","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/aje\/kwae379","article-title":"Thirty-five years of leaky vaccines","volume":"194","author":"Halloran","year":"2024","journal-title":"Am J Epidemiol"},{"key":"2026090221220231500_ref9","volume-title":"Causal Inference: What If","author":"Hernan","year":"2023"},{"issue":"1","key":"2026090221220231500_ref10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of Hazard ratios","volume":"21","author":"Hern\u00e1n","year":"2010","journal-title":"Epidemiology"},{"issue":"1","key":"2026090221220231500_ref11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/jme.2003.004440","article-title":"Challenge studies of human volunteers: ethical issues","volume":"30","author":"Hope","year":"2004","journal-title":"J Med Ethics"},{"issue":"0","key":"2026090221220231500_ref12","first-page":"1","article-title":"Quantification of vaccine waning as a challenge effect","volume":"0","author":"Janvin","year":"2024","journal-title":"J Am Stat Assoc"},{"key":"2026090221220231500_ref13","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268819001961","article-title":"Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results","volume":"147","author":"Lipsitch","year":"2019","journal-title":"Epidemiol Infect"},{"issue":"1","key":"2026090221220231500_ref14","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1038\/s41467-024-45549-9","article-title":"Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States","volume":"15","author":"Park","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"2026090221220231500_ref15","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/aje\/kwaf086","article-title":"Immune-selection stability is a neglected property of the causal risk ratio","volume":"195","author":"Piccininni","year":"2025","journal-title":"Am J Epidemiol"},{"issue":"7","key":"2026090221220231500_ref16","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/cid\/ciz706","article-title":"Depletion-of-susceptibles bias in analyses of intra-season waning of influenza vaccine effectiveness","volume":"70","author":"Ray","year":"2020","journal-title":"Clin Infect Dis."},{"issue":"30","key":"2026090221220231500_ref17","first-page":"2013","article-title":"Single world intervention graphs (SWIGs): a unification of the counterfactual and graphical approaches to causality","volume":"128","author":"Richardson","year":"2013","journal-title":"Center for the Statistics and the Social Sciences, University of Washington Series Working Paper"},{"issue":"9-12","key":"2026090221220231500_ref18","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/0270-0255(86)90088-6","article-title":"A new approach to causal inference in mortality studies with a sustained exposure period\u2014application to control of the healthy worker survivor effect","volume":"7","author":"Robins","year":"1986","journal-title":"Math Model"},{"issue":"25","key":"2026090221220231500_ref19","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa2116154","article-title":"Vaccine efficacy in adults in a respiratory syncytial virus challenge study","volume":"386","author":"Schmoele-Thoma","year":"2022","journal-title":"New Engl J Med"},{"issue":"544","key":"2026090221220231500_ref20","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1080\/01621459.2022.2071276","article-title":"Conditional separable effects","volume":"2023;118","author":"Stensrud","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"2026090221220231500_ref21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/EDE.0000000000001573","article-title":"Identification of vaccine effects when exposure status is unknown","volume":"34","author":"Stensrud","year":"2023","journal-title":"Epidemiology"},{"issue":"19","key":"2026090221220231500_ref22","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"New Engl J Med"},{"issue":"1","key":"2026090221220231500_ref23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/rssc.12033","article-title":"Time varying frailty models and the estimation of heterogeneities in transmission of infectious diseases","volume":"63","author":"Unkel","year":"2014","journal-title":"J R Stat Soc Ser C Appl Stat"},{"issue":"10002","key":"2026090221220231500_ref24","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/S0140-6736(15)60310-5","article-title":"Efficacy, safety, and immunogenicity of an oral recombinant helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"Zeng","year":"2015","journal-title":"The Lancet"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwag118\/68664880\/kwag118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/195\/9\/2469\/68664880\/kwag118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/195\/9\/2469\/68664880\/kwag118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:22:11Z","timestamp":1788398531000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/195\/9\/2469\/8722894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwag118","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,1]]}}}